Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol

Pharmacology and Toxicology

Volumn 88, Issue 1, 2001, Pages 34-39

  Sköld, Anna Carin ^a,b   Danielsson, Bengt R ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOKALANT; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EMBRYO DEVELOPMENT; FETUS DEVELOPMENT; FETUS GROWTH; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; NONHUMAN; POTASSIUM CURRENT; PREGNANCY; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; TOXICITY TESTING;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RODENTIA;

EID: 0035154499     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.088001034.x     Document Type: Article

References (22)

1. Abrahamsson, C., M. Palmer, B. Ljung, G. Duker, C. Bäärnhielm, L. Carlsson & B. Danielsson: Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc. Res. 1994, 28, 337-344.
2. Babin, J. P., M. Carre & C. Martin: Possible embryofetopathy caused by beta-blocker (sotalol) taken throughout the pregnancy. Pediatrie 1985, 40, 129-136.
3. Ban, Y., R. Konishi, K. Kawana, T. Nakatsuka, T. Fujii & J. M. Manson: Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch. Toxicol. 1994, 69, 65-71.
4. Beyer, T., J. Brachmann & W. Kubler: Comparative effects of d-sotalol and 1-sotalol on the atrioventricular node of the rabbit heart. Cardiovasc. Pharmacol. 1993, 22, 240-246.
5. Brent, R. L.: Relationship between uterine vascular clamping, vascular disruption syndrome, and cocaine teratogenicity. Teratology 1990, 41, 757-760 (Editorial comment).
6. Carlsson, L., C. Abrahamsson, B. Andersson, G. Duker & G. Schiller-Linhardt: Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res. 1993, 27, 2186-2193.
7. Carmeliet, E.: Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Therap. 1992, 262, 809-817.
8. Carmeliet, E.: Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ. Res. 1993, 73, 857-868.
9. Davies, M. P., R. H. An, P. Doevendans, S. Kubalak, K. R. Chien & R. S. Kass: Developmental changes in ionic channel activity in the embryonic murine heart. Circ. Res. 1996, 78, 15-25.
10. Erkkola, R., R. Lammintausta, P. Liukko & M. Anttila: Transfer of propranolol and sotalol across the human placenta. Their effect on maternal and fetal plasma renin activity. Acta obstet. gynecol scand. 1982, 61, 31-34.
11. Gustavsson, C. G., E. Vinge, B. O. Norlander & E. Pantev: Pharmacokinetic evaluation of a case of massive sotalol intoxication. Ann. Pharmacotherap. 1997, 31, 856-859.
12. Kowey, P. R., R. A. Marinchak, S. J. Rials & D. Bharucha: Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Amer. J. Cardiol. 1997, 80, 16G-23G.
13. Lynch, J. J. J., A. A. Wallace, L. H. Van der Gaag, E. P. Baskin, C. M. Bear, J. R. Gehret, T. Kothstein, R. F. Stupienski, S. D. Appleby & M. C. Sanguinetti: Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1′-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4′-piperidin]4-one HCl (L-691,121), a novel class III agent. J. Pharmacol. Exp. Therap. 1993, 265, 720-730.
14. MacNeil, D. J.: The side effect profile of class III antiarrhythmic drugs: focus on d,1-sotalol. Amer. J. Cardiol. 1997, 80, 90G-98G.
15. Marks, T. A. & R. D. Terry: Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 1996, 54, 157-164.
16. O'Hare, M. E, G. A. Murnaghan, C. J. Russell, W. J. Leahey, M. P. Varma & D. G. McDevitt: Sotalol as a hypotensive agent in pregnancy. Brit. J. Obstet. Gynaecol. 1980, 87, 814-820.
17. Sanguinetti, M. C. & N. K. Jurkiewicz: Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 1990, 96, 195-215.
18. Sköld, A-C. & B. R. Danielsson: Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Arzneimittelforsch. 2000, 50, 520-525.
19. Spence, S. G., C. Vetter & C. M. Hoe: Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos in vitro. Teratology 1994, 49, 282-292.
20. Wang, L., Z. P. Feng, C. S. Kondo, R. S. Sheldon & H. J. Duff: Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ. Res. 1996, 79, 79-85.
21. Webster, W. S., P. D. Brown-Woodman, M. D. Snow & B. R. Danielsson: Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 1996, 53, 168-175.
22. Wellfelt, K., A-C. Sköld, A. Wallin & B. R. Danielsson: Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod. Toxicol. 1999, 13, 93-101.